This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)

Group 1 - The average yield for blue chip dividend stocks is around 3% to 4%, making Pfizer's nearly 7% yield noteworthy and potentially suspicious [1] - Pfizer has consistently paid quarterly dividends for decades and has increased its annualized per-share dividend for 16 consecutive years [2] - The company's stock has declined significantly post-COVID, with annual revenue now approximately 40% below the 2022 peak of over $100 billion, indicating aggressive market pricing of this revenue decline [3] Group 2 - Pfizer aims to leverage its 2023 acquisition of Seagen to develop at least eight new blockbuster drugs by 2030, which could generate over $1 billion in annual sales each [4] - The company anticipates adding $20 billion to $25 billion in new revenue by 2030, which supports the potential for continued dividend growth [5] - Despite risks associated with R&D and the pharmaceutical industry, the current dividend yield suggests that much of this risk is already reflected in the stock price [6] Group 3 - The decline in Pfizer's stock is attributed to the end of a temporary revenue surge related to COVID, yet the ongoing developmental efforts are being overlooked by the market [8]